Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Europe has given limited approval to Lilly's Alzheimer's drug, President Trump has announced a trade deal with the EU, Delta ...

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...

A clinical trial of the drug Trontinemab will aim to delay or prevent the symptoms of Alzheimer's disease, Swiss drugmaker Roche says.

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Trontinemab is a formulation of Roche's failed gantenerumab but now paired with the company's Brainshuttle technology to ...